Printer Friendly

HOLOGIC SYSTEMS TO BE USED IN MAJOR STUDIES ON OSTEOPOROSIS

 HOLOGIC SYSTEMS TO BE USED IN MAJOR STUDIES ON OSTEOPOROSIS
 WALTHAM, Mass., Feb. 10 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) announced today that its QDR-2000 bone densitometry measurement systems will be used exclusively for two far-reaching studies on the effects of osteoporosis in women.
 One study is an 11-center, nationwide study to investigate if an experimental drug has an effect on the incidence of fractures in women aged 55-79. The domestic study is the first large-scale clinical trial of its kind in the country using human subjects.
 The second, a three-site international and domestic study, will seek to determine the relative incidence of new cases of osteoporosis among post menopausal women in a control population group -- one in which no drug therapy is administered -- and a group being treated by the experimental drug.
 Osteoporosis, a condition characterized by decreased bone density and increased risk of fracture, occurs in as many as two out of three women over the age of 65. It is estimated that some 20 million people are affected by osteoporosis. These studies are being conducted by Merck & Co., Inc.
 According to Hologic President S. David Ellenbogen, the QDR-2000, which recently received FDA clearance, is a third generation system for precisely determining bone mineral status. These instruments are used by physicians to monitor and diagnose osteoporosis and other bone mineral diseases. The QDR-2000 offers powerful improvements in technology and performance compared to conventional X-ray bone densitometers.
 The QDR-2000 is helpful to the research community by enabling researchers to determine if investigational drugs increase bone mass and to assess changes in bone mass from one part of the skeleton to another.
 "The QDR-2000 uses a fan-shaped X-ray beam and an array of 32 receptors to reduce scanning times to less than a minute and to improve image resolution," said Ellenbogen. "Such speed and precision accuracy is critical to clinicians and researchers such as those involved in the Merck studies."
 The QDR-2000 also offers researchers and other physicians the first and only method of reproducibly performing a lateral (side-to-side) scan of the lower spine without moving the patient. Physicians have suggested that lateral scanning is diagnostically more sensitive than conventional postero-anterior (back to front) scanning to identify osteoporotic patients. The QDR-2000 for the first time enables use of high-speed lateral scanning to follow patients in a clinically meaningful manner.
 The QDR-2000 is the third major advance in the field of osteoporosis pioneered by Hologic. The company introduced the industry's first X-ray bone densitometry machine, the QDR-1000, in 1987. An advanced system for whole body scanning, the QDR-1000/W, was introduced in 1989.
 Hologic, Inc. develops, manufactures and markets proprietary X-ray systems. With more than 800 installations worldwide, the company's QDR X-ray bone densitometers are used for the precise measurement of bone density.
 -0-
 /CONTACT: Drew Hall of Brodeur & Partners, 617-894-0003, for Hologic/ CO: Hologic, Inc. ST: Massachusetts IN: MTC SU:


TM-SH -- NE023 -- 8479 02/10/92 16:58 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1992
Words:488
Previous Article:CHECK TECHNOLOGY CORPORATION ANNOUNCES FIRST QUARTER RESULTS
Next Article:MATTEL DECLARES QUARTERLY DIVIDEND
Topics:


Related Articles
HEALTH CARE FINANCE ADMINISTRATION RECOMMENDS REIMBURSEMENT OF DUAL-ENERGY X-RAY EXAMINATIONS FOR OSTEOPOROSIS TESTING
HOLOGIC, INC. ANNOUNCES PRELIMINARY FISCAL AND FOURTH QUARTER 1994 OPERATING RESULTS
HOLOGIC FILES SUIT AGAINST COMPETITOR FOR PATENT INFRINGEMENT AND UNFAIR COMPETITION AND TRADE PRACTICES
HOLOGIC, INC. ANNOUNCES LATEST TECHNICAL INNOVATION IN BONE DENSITOMETRY
HOLOGIC, INC. ANNOUNCES SECOND QUARTER FISCAL 1995 OPERATING RESULTS AND DEVELOPMENT AGREEMENT WITH SEREX, INC.
HOLOGIC AND LUNAR SUSPEND PATENT LAWSUIT
HOLOGIC, INC. ANNOUNCES RECORD REVENUES IN FISCAL AND FOURTH QUARTER 1995
HOLOGIC, INC. ANNOUNCES RECORD REVENUES AND EARNINGS IN THE SECOND QUARTER OF FISCAL 1996
Hologic, Inc.: FDA Panel Recommends Approval with Conditions of Ultrasound Unit To Assist in the Diagnosis of Osteoporosis
Hologic and Caligor Sign Agreement for Distribution of Bone Densitometry Product Line.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters